Skip to main content
ImmuneCited

Vitamin D Immune Aging (Immunosenescence)

B

Research suggests vitamin D supplementation in elderly populations may help improve immune markers and vaccine response. Deficiency is highly prevalent in older adults and is associated with impaired immune function and increased infection susceptibility.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dvitamin\u002Dd\u0026condition\u003Dimmunosenescence'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

結論

Research suggests vitamin D supplementation in elderly populations may help improve immune markers and vaccine response. Deficiency is highly prevalent in older adults and is associated with impaired immune function and increased infection susceptibility.

Key Study Findings

Review
Fanconi anaemia as a human model of accelerated epigenetic and immune ageing.
Dose: None vs: None Outcome: None 効果: None None

対象集団: patients with Fanconi anaemia

Randomized Controlled Trial n=124
Effects of a Novel Dispersible Supplement Containing 2500 IU of Vitamin D and 1000 µg …
Dose: 2500 IU vitamin D + 1000 mcg B12 vs: Separate D+B12 and no supplementation control Outcome: Serum 25-OH-D and B12 level restoration 効果: 37.1% adequate vs 29.4% separate None

対象集団: Adults with vitamin D (<20ng/mL) and B12 (<250ng/L) insufficiency

Observational Study n=72
Cardiovascular Risk and Systemic Inflammation in Alopecia Areata: An Observational Case-control Study.
Dose: None vs: Healthy controls Outcome: CVR and systemic inflammation in alopecia areata 効果: None None

対象集団: 36 AA patients vs 36 matched controls, mean age 39

Controlled Clinical Trial
Vitamin D stimulates Il-15 synthesis in rodent muscle.
Dose: Single dose (rats); variable (in vitro) vs: Untreated controls; VDR-KO mice Outcome: IL-15 gene expression in skeletal muscle 効果: None None

対象集団: C2C12 myotubes, rats, VDR-KO mice

Randomized Controlled Trial 8 weeks
Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus …
Dose: Topical ointment application (3 arms) vs: 3-arm: mometasone vs calcipotriol vs tacrolimus Outcome: SALT score change at 8 weeks 効果: None <0.001 (momet, calcipot)

対象集団: Patients with localized alopecia areata

Other
Modelling the influence of vitamin D and probiotics on inflammation and the intestinal microbiota in …
Dose: None vs: No supplementation (modeled) Outcome: Epithelial barrier integrity and immune response 効果: None None

対象集団: Older adults (mathematical model)

Key Statistics

10

研究数

5000

参加者数

Positive

B

グレード

Referenced Papers

Skin appendage disorders 2025 5 件の引用
Biochemistry and biophysics … 2025
Indian dermatology online … 2024 3 件の引用
The Cochrane database … 2024 1 件の引用
International journal of … 2023 54 件の引用
Autoimmunity reviews 2023 24 件の引用
Mini reviews in … 2023 9 件の引用
Physiological research 2021 2 件の引用
Journal of cachexia, … 2020 365 件の引用
Advances in chronic … 2019 326 件の引用
Actas dermo-sifiliograficas 2019 43 件の引用
European journal of … 2017 66 件の引用
Postepy dermatologii i … 2017 31 件の引用
World journal of … 2016 238 件の引用
Ageing research reviews 2016 142 件の引用
Postepy dermatologii i … 2016 59 件の引用
Indian dermatology online … 2016 51 件の引用
World journal of … 2015 62 件の引用
The American journal … 2014 125 件の引用
European journal of … 2012 225 件の引用
Inflammatory bowel diseases 2012 224 件の引用
Gerontology 2011 27 件の引用
Gastroenterology 2010 390 件の引用
Artificial organs 2006 76 件の引用
Aging cell 2004 102 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
600-800 IU/day
immunesupport:
1,000-2,000 IU/day
deficiencycorrection:
4,000-5,000 IU/day (under medical supervision)

上限量: 4,000 IU/day (100 mcg)

研究で検討された用量

用量 期間 効果 N
None -- Negative --
2500 IU vitamin D + 1000 mcg B12 -- Positive 124
None -- Negative 72
Single dose (rats); variable (in vitro) -- Positive --
Topical ointment application (3 arms) 8 weeks Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --

推奨摂取タイミング: With a meal containing fat for better absorption

Safety & Side Effects

報告されている副作用

  • Hypercalcemia at very high doses (nausea, vomiting, weakness)
  • Kidney stones with excessive long-term use
  • Constipation
  • Metallic taste

既知の相互作用

  • Thiazide diuretics (may increase risk of hypercalcemia)
  • Corticosteroids (reduce vitamin D absorption and metabolism)
  • Orlistat and cholestyramine (reduce fat-soluble vitamin absorption)
  • Statins (vitamin D may affect statin metabolism)

耐容上限摂取量: 4,000 IU/day (100 mcg)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Vitamin D help with Immune Aging (Immunosenescence)?
Based on 10 studies with 5,000 participants, there is moderate evidence from clinical studies that Vitamin D may support Immune Aging (Immunosenescence) management. Our evidence grade is B (Good Evidence).
How much Vitamin D should I take for Immune Aging (Immunosenescence)?
Studies have used various dosages. A commonly studied range is 600-800 IU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Vitamin D?
Reported side effects may include Hypercalcemia at very high doses (nausea, vomiting, weakness), Kidney stones with excessive long-term use, Constipation, Metallic taste. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Vitamin D and Immune Aging (Immunosenescence)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。